Clinical Coagulation, Malmö
11 – 20 of 628
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Acquired Haemophilia A in four north European countries : survey of 181 patients
(
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor IX Fc in Sweden : A report from the Swedish National Registry for bleeding disorders
(
- Contribution to journal › Letter
-
Mark
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
(
- Contribution to journal › Article
-
Mark
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B : post hoc analysis of phase III trials using patient-reported outcomes
(
- Contribution to journal › Article
-
Mark
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
(
- Contribution to journal › Article
-
Mark
Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation : Application of natural language processing to electronic medical records data
(
- Contribution to journal › Article
-
Mark
A need to increase von Willebrand disease awareness : vwdtest.com – A global initiative to help address this gap
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
-
Mark
Haemophilia B - Diagnostic Insights, Genetic Aspects and Clinical Outcomes
2023) In Lund University, Faculty of Medicine, Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
No difference in quality of life between persons with severe haemophilia A and B
(
- Contribution to journal › Article